When the results of cohort 2 and the expansion cohort were combined, a highly significant decrease in the percentage of Tregs was observed, both within the combined patient cohort as well as in comparison of this cohort to cohort 0 (Fig. 1 b).
← all excerpts
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.
1
—
—